Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420634 | 1.00 | METAP2 (0.32) | METAP2METAP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3419654 | 0.90 | — | — | |
| SCHEMBL3421223 | 0.66 | — | — | |
| SCHEMBL3420184 | 0.66 | — | — | |
| SCHEMBL25191603 | 0.64 | — | — | |
| SCHEMBL21596751 | 0.64 | ZDHHC7 (0.34) | — | |
| SCHEMBL21596750 | 0.64 | ZDHHC7 (0.34) | — | |
| SCHEMBL6764213 | 0.61 | ALDH1A1 (0.44) | — | |
| SCHEMBL6764215 | 0.61 | ALDH1A1 (0.44) | — | |
| SCHEMBL21596759 | 0.58 | ACE (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167463-B1 | CYSTEINE DERIVATIVES WHICH COUNTERACT MALODOUR | GIVAUDAN SA (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-7846887-B2 | Cysteine derivatives which counteract malodour | GIVAUDAN SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20100179088-A1 | Cysteine Derivatives Which Counteract Malodour | GIVAUDAN SA (CH) | 2010-07-15 | — | — | US | disclosed |
| EP-2167463-A1 | CYSTEINE DERIVATIVES WHICH COUNTERACT MALODOUR | Givaudan SA (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-2022780-A2 | Cysteine derivatives which counteract malodour | Givaudan SA (CH) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154765-A1 | CYSTEINE DERIVATIVES WHICH COUNTERACT MALODOUR | GIVAUDAN SA (CH) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179088-A1 | Cysteine Derivatives Which Counteract Malodour | CBR3, CBR1, GSR | METAP2 424/4885METAP1 142/4885CYP1A2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.